EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)

Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.582
https://www.valueinhealthjournal.com/article/S1098-3015(23)03712-9/fulltext
Section Title :
Section Order : 10075
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03712-9&doi=10.1016/j.jval.2023.09.582
HEOR Topics :
Tags :
Regions :